CJC-1295
See our Evidence Standards for how we grade the research below.
What It Is
CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH), engineered with amino acid substitutions that resist enzymatic breakdown, giving it a longer active window than natural GHRH or unmodified sermorelin. It binds the same GHRH receptor on pituitary somatotrophs as endogenous GHRH, stimulating a more physiologic, pulsatile pattern of GH release rather than driving GH secretion independent of the body's own feedback controls.
The Evidence
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." Journal of Clinical Endocrinology & Metabolism. 2006 Mar;91(3):799-805. PMID: 16352683. Two randomized, double-blind, placebo-controlled, ascending-dose trials (28 and 49 days) in healthy adults aged 21-61, using CJC-1295 with DAC. The first trial tested single ascending subcutaneous doses; the second tested two or three weekly or biweekly doses. A single injection produced dose-dependent increases in GH (2- to 10-fold above baseline) lasting 6 or more days, and IGF-1 increases (1.5- to 3-fold) lasting 9 to 11 days. Measured half-life was 5.8 to 8.1 days. With multiple doses, IGF-1 stayed above baseline for up to 28 days, with evidence of a cumulative effect. No serious adverse reactions were reported, and the compound was described as safe and well tolerated, particularly at the 30 or 60 mcg/kg doses tested.
Alba M, Fintini D, Sagazio A, et al. "Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse." PMID: 16822960. Preclinical study in mice genetically unable to produce GHRH. Daily CJC-1295 normalized body weight and length; less frequent dosing (every 48 or 72 hours) produced partial but incomplete normalization. Treated mice showed increased pituitary GH mRNA and evidence of somatotroph cell proliferation.
What's Reported in Practice
Patients and providers commonly report improved sleep quality, better recovery, and gradual improvements in body composition with CJC-1295, particularly when paired with a ghrelin mimetic like ipamorelin. These reports are consistent with what we'd expect mechanistically from sustained GH-axis stimulation, and we think they're a real signal worth further study. They have not been demonstrated in a controlled trial measuring those specific outcomes, so we present them as reported experience rather than established evidence.
What the Research Doesn't Yet Show
This is where we're most eager to see more research investment, not a mark against the compound. The Teichman trial is a well-designed, real human RCT, but it was a pharmacokinetic and safety study in healthy volunteers, not an outcomes trial; it measured GH and IGF-1 levels, not body composition, strength, sleep, or quality of life. It also tested the DAC form exclusively, at durations up to 49 days, while much of current clinical use involves the non-DAC form dosed daily over months, a regimen this trial doesn't speak to directly. We did not identify a controlled trial measuring real outcomes (body composition, strength, sleep quality) for either form of CJC-1295, or a trial testing the combination with ipamorelin specifically. Those are exactly the studies that would let the reported clinical benefits be properly tested, and the existing PK and safety data provide a reasonable foundation for designing them.
Compounded, not FDA-approved for this indication. Sourcing and availability are discussed at your visit.
Next Step
This page covers mechanism and evidence. Dosing, cycling, which form (DAC or non-DAC) may be right, and whether this is appropriate for you are individual clinical decisions made with your provider.
Already a patient? Bring this up at your next 4Ever Young visit. Have a question first?